Acute respiratory failure with bilateral pulmonary infiltrates is a clinical problem with a wide differential diagnosis. We evaluated whether open lung biopsy offered a diagnosis and therapeutic guidance in cases of unclear diagnosis after non-invasive tests. For this purpose, we reviewed 60 cases of open lung biopsy performed between 2002 and 2009 in patients with acute respiratory failure and bilateral infiltrates at the intensive care unit of Ghent University Hospital. Pathological diagnosis was classified as specific or non-specific and its contribution to therapy and decision-making was evaluated by a panel of three intensive care unit physicians. We found that a specific pathological diagnosis was present in 39 open lung biopsy patients (65%; 95% confidence interval 52 to 76%): idiopathic interstitial pneumonia in 24 patients, malignancy in four patients, pulmonary infectious disease in nine patients, and a combination of specific diagnoses in two patients. Open lung biopsy contributed to patient management in 53 cases (88%) as it led to the initiation, modification or discontinuation of therapeutic drugs in 36, and contributed to the decision to continue or withdraw ventilator support in 17. Complications of open lung biopsy were noted in 14 patients (23%). We conclude that open lung biopsy was a useful diagnostic intervention in of a selected group of patients with acute respiratory failure and bilateral infiltrates of unclear clinical diagnosis, as it offered a specific diagnosis in 65%.
Acute respiratory failure (ARF) with bilateral, diffuse infiltrates on chest X-ray is a common clinical problem in the intensive care unit (ICU). In the absence of cardiac failure or fluid overload this condition, occurring within a week after a known clinical insult or new or worsening respiratory symptoms, complies with a clinical diagnosis of acute respiratory distress syndrome (ARDS) 1,2 . However, rather than natural disease with a single cause, ARDS represents an inflammatory host response to a wide array of insults 3 . In addition, other diseases affecting the lung may be clinically indistinguishable from ARDS 4 .
Mechanical ventilation averts immediate mortality due to hypoxaemia in most patients, but the ultimate survival depends on the resolution of the pulmonary injury. This requires reversal of the cause as well as modulation of the host response, especially in ARDS where lung inflammation and remodelling may be mitigated by corticosteroid therapy 5 . In most instances, such as bacterial infection, gross aspiration or major trauma or surgery, the cause of ARF is easily deduced from the clinical presentation together with routine biochemical, microbiological and radiological data. However, in some ARF patients, routine diagnostic workup is unable to identify the underlying cause or disease. Similarly, it may provide insufficient information in therapeutic dilemmas such as whether or not to start corticosteroid therapy when this can be potentially detrimental, or to continue empirical antimicrobial therapy when this can be potentially toxic.
In addition, failure to discern ARDS from diffuse pulmonary infiltrates caused by interstitial lung disease or malignancy may lead to inappropriate treatments or decisions. When identification of the cause of ARF is felt to be essential to direct therapy or estimate prognosis, open lung biopsy (OlB) has been advocated as a ultimate diagnostic tool following inconclusive non-invasive techniques 4, [6] [7] [8] [9] [10] [11] .
In this paper, we report on our experience with OlB in mechanically ventilated patients with hypoxaemic ARF and bilateral pulmonary infiltrates and with unclear diagnosis following non-invasive diagnostics. We classified the results as specific or as non-specific diagnoses and evaluated the contribution of OlB to therapy and decision-making.
MATERIAlS AND METHODS

Patients
This retrospective study was conducted at the 54bed ICU of Ghent University Hospital, a 1054-bed tertiary hospital. We reviewed all cases of OlB in patients receiving mechanical ventilation for hypoxaemic ARF with bilateral pulmonary infiltrates between 2002 and 2009. Only cases in which it was decided to proceed with OlB after ICU admission because of ARF were considered for analysis, excluding those patients with OlB planned by the referring physician prior to ICU admission. Patients in whom lung tissue was biopsied during thoracotomy for pulmonary resection were also excluded.
Data
We recorded demographic data (age and sex), comorbidity, reason for ICU admission, antibiotic and corticosteroid therapy prior to OlB, duration of mechanical ventilation prior to OlB, and ICU mortality. We noted the results of bronchoalveolar lavage (BAl) and of high-resolution computed tomography (HRCT) of the lungs, performed prior to the decision for OlB. Pathological diagnosis of lung biopsy was classified as specific or non-specific.
As specific diagnosis we considered: 1) idiopathic interstitial pneumonia (as classified by the 2001 American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias) 12 ; 2) malignancy; 3) infection with identification of the causative pathogen; and 4) a combination of previous diagnoses.
Pathological findings compatible with various stages of ARDS (diffuse alveolar damage, fibroproliferative phase) or with organising pneumonia with bronchiolitis obliterans (BOOP) were considered as non-specific as these events are considered to be the sequential evolution of vascular failure or infectious conditions. We estimated the total number of patients diagnosed with ARDS in our hospital during the study period by querying the Minimum Basic Data Set used by Belgian hospitals to register casemix data for each admission to obtain reimbursement from the authorities.
The contribution of OlB to clinical decisionmaking was retrospectively assessed by a panel of three ICU physicians (PD, DB, JD). OlB was considered as contributive when a specific or a nonspecific pathological diagnosis led to a change in therapy defined as: 1) discontinuation of empiric antibiotic therapy or corticosteroids; or 2) change, addition or initiation of directed antibiotic therapy or corticosteroids. OlB was also considered as contributive if a pathological diagnosis had a major influence on the decision whether to prolong or discontinue mechanical ventilator support. All cases were resolved by consensus.
The study was approved by the Ethics Committee of Ghent University Hospital (Approval No. B670-20097158) and informed consent was waived due to the retrospective nature of the study.
Diagnostic procedures
Patients with ARF and diffuse bilateral infiltrates with no obvious aetiology and patients with nonresolving ARDS (defined as lack of resolution of infiltrates and hypoxaemia despite recovery of other organ failure) undergo HRCT to aid in differential diagnosis and to select the preferential site for BAl or OlB.
BAl is performed with fibreoptic guidance and is directed at the radiologically most affected site. Three to five aliquots of 10 ml saline are instilled and aspirated back and the pooled sample is directly examined for presence of micro-organisms, followed by culture for bacteria, fungi, Pneumocystis jirovecii, Legionella sp., mycobacteria and (in immunocompromised patients) respiratory viruses.
OlB is performed at the operating theatre by senior thoracic surgeons. The site of biopsy is determined preoperatively by agreement between the critical care physician and the surgeon after consulting the HRCT. All patients undergo a 10 cm anterior thoracotomy in the fifth intercostal space, after which pulmonary tissue and pleural cavity is visually and manually explored. Pleural fluid is collected for analysis, if present. A biopsy is taken from a macroscopically affected site; this specimen is divided for microbiological and pathological analysis. Two chest tubes are left for drainage of air and fluid. The whole procedure usually takes about 30 minutes.
Surgical specimens are put in a receptacle on ice and sent immediately to the laboratories for pathology and microbiology. The triangular fragments are stitched at two sides leaving the pleural side PEEP=positive end-expiratory pressure.
untouched. A gentle injection into the lung parenchyma is carried out with a 10 ml syringe containing buffered formaldehyde 4%, using an 18 G needle. The injection is performed at multiple sites of the sample avoiding high pressure artefacts. The biopsy is soaked into the fixative fluid for another six hours and covered with wet paper to avoid dehydration as the biopsy floats. After the appropiate fixation time, the fragment is then cut in thin slices with a thickness of 2 to 3 mm and further processed for paraffin embedding. Haematoxylin and eosin, trichrome and elastin stains are performed for routine analysis on light microscopy. Statistical analysis was performed using SPSS for Windows, Version 15 (IBM, New york City, Ny, USA). Continuous variables are described as mean (± standard deviation) or as median (interquartile range), and categorical variables are described as counts (percentage). For comparative tests on categorical variables, the Pearson chi-square test was used. Survival curves were generated according to the Kaplan-Meier method with vital status at hospital discharge as the response variable and using the log Rank test to address survival probability differences between subgroups. All reported P values are two-tailed and are considered statistically significant when less than 0.05.
RESUlTS
We identified 60 cases of OlB fulfilling our case definition. The total number of patients ventilated for at least 48 hours during the study period was around 7000; ARDS was diagnosed in 1505 patients, of which 872 had a diagnosis of ARDS following shock, trauma or surgery. Patient demographics, relevant comorbidities, clinical characteristics prior to the decision to proceed to OlB, as well as findings of HRCT and BAl are detailed in Table  1 . In 49 patients, the admission diagnosis was acute respiratory failure of unknown origin; in 31 of these, respiratory symptoms were present for a few days (acute onset) and in 14 patients, the onset of respiratory complaints could be traced back a few weeks (subacute onset). Three patients were admitted with bacterial pneumonia (Legionella pneumophila in two patients, hospital-acquired pneumonia with Escherichia coli in one) and one patient was intubated because of an infectious exacerbation of chronic obstructive pulmonary disease, followed by ventilator-associated pneumonia caused by Stenotrophomonas maltophilia. Ten patients were diagnosed with ARDS; the underlying cause was major thoracic surgery in three patients, septic shock in six patients and Paraquat poisoning in one patient. Thirty-three patients (56%) were immunocompromised: 12 had haematological malignancy, seven had received a solid organ transplant, 12 had received high-dose corticosteroids or other immunomodulating drugs for disease with systemic inflammation, and two were human immunodeficiency virus-positive. Five patients had known underlying solid malignancy. Three patients had a history of suspected or proven interstitial lung disease: non-specific interstitial pneumonia (NSIP) in one patient, sarcoidosis in one patient (both proven by histology) and asbestosis in one patient (clinico-radiological diagnosis only).
The median duration of mechanical ventilation prior to OlB was two days (1 to 28). All but one patient (98%) had received empirical therapy prior to OlB: antimicrobial therapy in 22 patients (37%), corticosteroids in one patient (2%) and a combination of antimicrobials and corticosteroids in 36 patients (60%). All patients underwent BAl Bronchiolitis obliterans organising pneumonia 3 5%
Absence of pathological findings 1 2%
ARDS=acute respiratory distress syndrome.
prior to OlB. In eight patients, polymerase chain reaction testing for cytomegalic virus was performed, with a marginally positive result in one patient.
OlB provided a specific diagnosis in 39 cases (65%; 95% confidence interval 52 to 76%). Idiopathic interstitial pneumonia was diagnosed in 24 cases: NISP in eight patients, usual interstitial pneumonia (UIP) in eight patients, desquamative interstitial pneumonia in seven patients, and acute fibrinous and organising pneumonia in one patient. Infectious disease was documented in nine patients: staphylococcal abscesses in one patient, invasive aspergillosis in three patients, toxoplasmosis in one patient, cytomegalovirus (CMV) pneumonia in one patient, cryptococcal pneumonia in one patient, respiratory syncytial virus pneumonia in one patient, and both Pneumocysis jirovecii pneumonia and invasive aspergillosis in one patient. Malignancy was found in four patients. One patient had both malignancy and toxoplasmosis and one patient had desquamative pneumonia and invasive aspergillosis. The remaining 21 cases of OlB showed nonspecific results: diffuse alveolar damage in three patients, organising or fibro-proliferative ARDS in 14 patients, BOOP in three patients, and absence of pathological findings in one patient.
The results of OlB contributed to therapy or decision-making in 53 cases (88%; 95% confidence interval 78 to 94%). In all 39 cases with a specific diagnosis, therapy was adjusted according to OlB results: new anti-microbials were introduced in ten patients and corticosteroids were introduced or adjusted in 15 patients. In 14 patients, a decision for palliative care with withdrawal of organ support was taken. In addition, OlB had an impact on therapy in 14 of 21 cases with a non-specific diagnosis: in six patients corticosteroid therapy was initiated or continued (after aspergillosis was ruled out), in three patients empirical and potentially toxic anti-infectious therapy (high-dose trimethoprimsulfamethoxazole in two patients, ganciclovir in one patient) was discontinued, and in two patients, empirical antimicrobial therapy was discontinued while corticosteroids were started, in two patients mechanical ventilation was continued (after malignancy and end-stage fibrosis were ruled out), in one patient mechanical ventilation was withdrawn (after treatable infection was ruled out). ICU mortality in patients with a specific diagnosis was 80% as compared to 40% in patients with a nonspecific diagnosis (P=0.001); in both groups hospital mortality was 82 and 62%, respectively (P=0.12). A Kaplan-Meier survival curve is provided Figure 1 .
Complications of OlB occurred in 14 patients (23%). Eight patients had a significant air leak (lasting more than seven days); this was accompanied by subcutaneous emphysema in three patients, and by pneumothorax in three patients; in one of these patients, obstruction of chest tube drainage led to tension pneumothorax. In addition, four patients had bloody pleural effusion following OlB, in excess of one litre in two patients, but none requiring surgical revision. lobar atelectasis with temporarily increased oxygen requirements was diagnosed in two patients.
DISCUSSION
In our series of 60 cases selected for OlB because of hypoxaemic ARF with bilateral infiltrates and unknown aetiology, a specific pathological diagnosis was found in 65% and the histological findings were contributive to therapy or decisionmaking in 88%. These figures are congruent with those of previous retrospective reports [6] [7] [8] [9] [10] , as well as with that of the single prospective study 11 . However, in contrast to most other reports, we found that 
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Non-invasive testing provided diagnosis (post hoc) a specific diagnosis was associated with increased mortality. This apparently contradictory finding is explained by a high prevalence in our series of cases with a specific diagnosis representing diseases mimicking ARDS and with a poorprognosis 4 , rather than aetiologies known to induce ARDS. As such, OlB is unlikely to have contributed to better outcome of this patient group in terms of survival; however the information obtained from OlB was helpful to provide appropriate care in the majority of these cases, including adequate prognostication torelatives, withdrawal of likely futile life support and replacing aggressive with palliative treatment. The most common specific diagnosis in our patients was diffuse lung disease in the group of idiopathic interstitial pneumonia 12 . Idiopathic interstitial pneumonia usually presents as slowly progressive dyspnoea and non-productive cough with insidious onset, although the clinical-pathological entity of acute interstitial pneumonia is distinguished by a short interval (weeks) between initial symptoms and full-blown respiratory failure. In addition, an accelerated phase has been described in UIP, characterised by an exacerbation of symptoms with relentless progression towards refractory respiratory failure over the course of a few weeks 13 . In less than half of our cases we could document a subacute onset of respiratory symptoms evolving over weeks, and only three patients had a history of interstitial lung disease; all other patients presented with ARF developing within the course of a few days. Although in some of these patients HRCT showed signs of fibrosis, groundglass opacities were predominant and radiographic findings in the absence of a diagnosis of underlying disease were felt to present insufficient evidence to set goals for corticosteroid therapy or to decide for withdrawal of mechanical ventilatory support. While HRCT findings reflective of widespread fibrosis (such as extensive remodelling with honeycombing and traction bronchiectasis) in ARF patients with poor performance or higher age may render invasive diagnostics obsolete and justify therapeutic limitation, histology is usually required in less clearcut cases, especially given the important prognostic information associated with it [14] [15] [16] . Particularly, a clear and reliable distinction has to be made between UIP, which has a dismal prognosis and no realistic therapeutic options in ventilated patients 17, 18 , and other types of interstitial pneumonia such as NSIP, where a trial of corticosteroid or other immunomodulating drug is warranted before definitive conclusions about futility of treatment can be taken.
Half of the patients selected for OlB had underlying immunosuppression. Differential diagnosis of ARF with diffuse infiltrates is particularly broad and challenging in these patients and the ability to identify its cause is strongly linked with outcome. Prior to OlB, all of our patients underwent BAl which remained inconclusive. Whereas most BAl cultures were negative, some BAl fluids yielded bacterial or fungal pathogens which were not interpreted to represent a cause of ARF, but nosocomial infection or colonisation instead. The potential of BAl to identify the cause of ARF has most extensively been studied in patients with immunosuppression or underlying malignancy. In these studies, BAl failed to provide a diagnosis in more than half of the cases [19] [20] [21] . The main contribution of BAl is in the detection of infectious pathogens 20, 22 ; differential analysis of cellular composition of BAl fluid may help to differentiate various infectious and non-infectious diffuse pulmonary diseases 4 , but has to our knowledge never been evaluated in patients with ARF requiring mechanical ventilation. In a prospective study on OlB in 100 patients with persisting ARDS and microbiologically negative BAl, BAl cytology, despite being performed on all BAl samples, was not reported to contribute to diagnosis 11 . In mechanically ventilated patients, the frequent empirical use of antimicrobial drugs and of corticosteroids, as well as the higher risk for intercurring nosocomial pneumonia, is likely to obscure the cytological pattern of the underlying disease and to preclude firm conclusions towards therapy and prognosis.
Other non-invasive testing was limited to polymerase chain reaction test for CMV in patients at risk for, and with a clinical syndrome compatible with, CMV disease. Judged retrospectively from the biopsy results, it is unlikely that a more standardised and complete non-invasive testing panel would have contributed significantly to diagnosis and would have obviated the need for OlB. In a prospective randomised study on diagnostic techniques in immuno-compromised patients, polymerase chain reaction test for CMV and serology for atypical respiratory pathogens yielded a definitive diagnosis only in 1.5 and 3% of patients tested, respectively 23 . Other non-invasive tests are more likely to have reduced the need for OlB in our patients however. We did not analyse galactomannan levels in serum or BAl, as these techniques were not yet available in our institution at the time of the study. As galactomannan in BAl has been shown to have good sensitivity and specificity, it may have obviated OlB in those cases where a clinical suspicion of aspergillosis, in the absence of microbiological data, had to be confirmed or ruled out 22 .
Since the advances in critical care allow for prolonged organ support even in disease unresponsive to treatment, patient death is often preceded by a medical decision rather than uncontrollable physiological deterioration. Clinical decision-making in the face of uncertainty is a complex process and when decisions have a direct and profound impact on immediate outcome, such as those regarding withdrawal of mechanical ventilation, the tolerated degree of uncertainty is evidently less 24 . In our series, OlB had an impact on therapy or decisionmaking in 88% of cases. Some contribution of OlB was major, such as regarding withdrawal of ventilatory support in patients with proven UIP. In other cases, as in patients with a diagnosis of NSIP or desquamative interstitial pneumonia and already treated empirically with corticosteroids, histological diagnosis led to some small immediate adjustments in corticosteroid therapy only. yet, it can be argued that differentiating fibro-proliferative ARDS from underlying idiopathic interstitial pneumonia has important consequences for planning long-term therapy (duration of corticosteroid therapy, use of alternative immunomodulating drugs), and estimating prognosis.
Complications of OlB were noted in a quarter of patients and consisted mainly of air leak or bleeding, which is not unexpected in the context of diffuse parenchymal disease. However, we found no association between the occurrence of complications and the presence and extent of fibrosis on histology. None of the complications was judged to have contributed to mortality, but the impact of these complications on e.g. duration of mechanical ventilation was difficult to disentangle from that of the histological diagnosis, and may have been obscured by withdrawal of ventilatory support in some patients.
A major limitation of our study originates from its retrospective design, which precludes firm recommendations for the selection of patients who could potentially benefit from OlB. Our case series is not representative for the overall population of patients with ARDS, but instead constitutes a highly selected patient population, in whom underlying risk factors (immunosuppression, history of malignancy) or an unfavourable clinical course provoked the clinician to pursue an aggressive search for an aetiologic diagnosis. As such, the high estimate of the contribution of OlB to decisionmaking cannot be translated to the overall population with ARDS. However, all patients who underwent OlB represent a frequently encountered clinical conundrum, that of a critically ill patient being mechanically ventilated for diffuse pulmonary disease, not resolving under empirical therapy and evading prognostic assessment. As such, our study confirms other reports which have showed that OlB is a valuable diagnostic tool in mechanically ventilated patients after equivocal non-invasive testing, as it couples a large residual discriminative potential with an acceptable complication rate.
